Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Phase I clinical trial of the farnesyltransferase (FT) inhibitor BMS-214662 in patients with advanced solid tumors

Phase I clinical trial of the farnesyltransferase (FT) inhibitor BMS-214662 in patients with advanced solid tumors. Journal of Clinical Oncology, ASCO Annual Meeting Proceedings. 2000.


Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.